Menu
Indications for DARZALEX®[1]
DARZALEX® for multiple myeloma
Frontline transplant-eligible
Frontline transplant-ineligible
From 2nd line
From 3rd line
DARZALEX® for AL amyloidosis
Newly-diagnosed
DARZALEX® practical guides
SC Checklist beginning of treatment
Includes a first use checklist of Darzalex® SC.
Darzalex® SC Practical Guide
Includes DARZALEX® SC handling and administration info, pre and post-injection medications, and more
Dosing schedules for all Darzalex® treatment regimens
Find more about DARZALEX® and multiple myeloma
.png?width=690&height=388&format=webp&quality=50)
Prof. Mateos presents 4-year updates of POLLUX study
María-Victoria Mateos of Hospital Universitario de Salamanca
21 February 2020 ASH 2019
Prof. Mateos presents 4-year updates of CASTOR study
María-Victoria Mateos of Hospital Universitario de Salamanca
21 February 2020 ASH 2019
ALCYONE update
Prof. María-Victoria Mateos presents 1-year updates from ALCYONE
DARZALEX® SC practical guidance
DARZALEX® SC preparation
An interactive video covering the key facts about the handling, preparation and administration of DARZALEX® SC
DARZALEX® SC studies
DARZALEX® SC STUDIES
In this interactive video, Prof. Mateos gives an overview of the DARZALEX® SC PAVO, COLUMBA and PLEIADES studies.
Patient materials
Supporting patients on their journey
Access downloadable patient materials to help your patients and their caregivers on their journey with MM treatment
DARZALEX® is the first approved CD38‑targeting immunotherapy for multiple myeloma (MM)[2]
Glossary
AL: amyloid light chain
IRR: infusion-related reaction
MM: multiple myeloma
MOA: mode of action
Rd: lenalidomide, dexamethasone
SC: subcutaneous
VCd: Velcade®, cyclophosphamide, dexamethasone
Vd: Velcade®, dexamethasone
VMP: Velcade®, melphalan, prednisone
VTd: Velcade®, thalidomide, dexamethasone
